| At present, the company produces a range of fine chemicals and pharmaceutical products which account for around 40 per cent of its turnover and 45-50 per cent of its profits. |
| "This is a part of our efforts to move up the value chain," Jubilant Organosys chairman Shyam Bhartiya said. |
| The company had entered the bulk drugs business last year when it acquired the Nanjundgod plant of Max India. It is now seeking to produce formulations. |
| "We could go for an acquisition to make formulations if it adds value to our business. Otherwise, we could set up a greenfield plant," Bhartiya said, adding that Jammu & Kashmir could be a good option for such a venture because of the tax sops offered by the state government. |
| Bhartiya said Jubilant Organosys would target opportunity in the generics market that is being thrown open in the US and Europe with a large number of drugs going off patent. |
| Estimates suggest that drugs with sales worth $55-60 billion will go off patent in the next few years. |
| On the company's plan for its pharmaceuticals business in the US, Bhartiya said the company would supply to generic companies and not market drugs on its own as it involves huge costs. |
| "But we could acquire a company there which would help us in understanding the market," he said. |
| Bhartiya said growth is expected to come with a thrust on international sales, innovations and research and development, and maximisation of operational efficiencies. |
| "Net sales have recorded a growth of 46 per cent and profit after tax has grown by 107 per cent in the first five months of this fiscal," he said. |
| Though the company aims to make pharmaceutical and life science as its main business, Bhartiya said there were no plans to exit from specialty chemicals as it is still profitable. |
Top Section
Explore Business Standard